Affinity Asset Advisors, LLC
- SEC CIK
- 0001773195
Holdings, Q2 2026
Positions as of Jun 30, 2026, filed Aug 13, 2026.SEC
- Positions
- 104
- +9 vs. Q1 2026
- Total value
- $2.04B
- +$339.74M (+19.9%) vs. Q1 2026
Compare with Q1 2026: new, added, reduced and sold out
Positions
Long positions only. Changes compare share counts with Q1 2026.
| Security | Class | Shares | Value | % of portfolio | Change in shares | Action | History |
|---|---|---|---|---|---|---|---|
| ROIVROIVANT SCIENCES LTD | SHS | 3,750,000 | $132.71M | 6.49% | +950,000+33.9% | Added | View |
| APOGEE THERAPEUTICS INC03770N101 | COM | 987,000 | $131M | 6.41% | −297,926−23.2% | Reduced | – |
| SYRESPYRE THERAPEUTICS INC | COM NEW | 1,279,134 | $113.56M | 5.55% | 00.0% | Unchanged | View |
| XENEXENON PHARMACEUTICALS INC | COM | 1,595,000 | $96.27M | 4.71% | −80,000−4.8% | Reduced | View |
| ERASERASCA INC | COM | 5,250,000 | $96.18M | 4.70% | −100,000−1.9% | Reduced | View |
| INSMINSMED INC | COM PAR $.01 | 650,000 | $69.3M | 3.39% | +170,000+35.4% | Added | View |
| PRAXPRAXIS PRECISION MEDICINES I | COM NEW | 185,000 | $61.94M | 3.03% | +15,000+8.8% | Added | View |
| ALKSALKERMES PLC | SHS | 1,125,000 | $58.94M | 2.88% | −225,000−16.7% | Reduced | View |
| ORKAORUKA THERAPEUTICS INC | COM | 590,000 | $56.15M | 2.75% | +90,327+18.1% | Added | View |
| ANABANAPTYSBIO INC | COM | 826,109 | $55.76M | 2.73% | −113,891−12.1% | Reduced | View |
| AVTXAVALO THERAPEUTICS INC | COM NEW | 2,900,000 | $53.59M | 2.62% | +1,559,160+116.3% | Added | View |
| CYTKCYTOKINETICS INC | COM NEW | 550,000 | $46.85M | 2.29% | −150,483−21.5% | Reduced | View |
| RVMDREVOLUTION MEDICINES INC | COM | 250,000 | $46.82M | 2.29% | +150,000+150.0% | Added | View |
| ABVXABIVAX SA | SPONSORED ADS | 330,000 | $43.98M | 2.15% | −75,000−18.5% | Reduced | View |
| TRAXFIRST TRACKS BIOTHERAPEUTICS | ORD SHS | 2,032,012 | $40.88M | 2.00% | +2,032,012 | New | View |
| DNTHDIANTHUS THERAPEUTICS INC | COM | 400,000 | $38.99M | 1.91% | +50,000+14.3% | Added | View |
| STROSUTRO BIOPHARMA INC | COM SHS | 1,172,487 | $38.93M | 1.90% | +102,968+9.6% | Added | View |
| NUVALENT INC670703107 | COM | 275,000 | $33.96M | 1.66% | −25,000−8.3% | Reduced | – |
| TRVITREVI THERAPEUTICS INC | COM | 1,800,172 | $33.57M | 1.64% | −200,000−10.0% | Reduced | View |
| OVIDOVID THERAPEUTICS INC | COM | 10,144,562 | $27.29M | 1.33% | −491,756−4.6% | Reduced | View |
| LXEOLEXEO THERAPEUTICS INC | COM | 5,807,611 | $27.03M | 1.32% | +757,400+15.0% | Added | View |
| CLDXCELLDEX THERAPEUTICS INC NEW | COM NEW | 700,000 | $26.05M | 1.27% | +200,000+40.0% | Added | View |
| BLTEBELITE BIO INC | SPONSORED ADS | 165,000 | $25.41M | 1.24% | +100,000+153.8% | Added | View |
| ELVNENLIVEN THERAPEUTICS INC | COM | 500,000 | $25.38M | 1.24% | −86,904−14.8% | Reduced | View |
| FORTE BIOSCIENCES INC34962G208 | COM NEW | 1,145,391 | $24.34M | 1.19% | +133,501+13.2% | Added | – |
| NRIXNURIX THERAPEUTICS INC | COM | 967,620 | $23.47M | 1.15% | 00.0% | Unchanged | View |
| ANROALTO NEUROSCIENCE INC | COM SHS | 850,000 | $22.43M | 1.10% | +350,000+70.0% | Added | View |
| MDGLMADRIGAL PHARMACEUTICALS INC | COM | 40,000 | $21.48M | 1.05% | −15,000−27.3% | Reduced | View |
| PTGXPROTAGONIST THERAPEUTICS INC | COM | 172,125 | $21.1M | 1.03% | 00.0% | Unchanged | View |
| MLYSMINERALYS THERAPEUTICS INC | COM | 750,000 | $20.24M | 0.99% | 00.0% | Unchanged | View |
| RLAYRELAY THERAPEUTICS INC | COM | 1,050,000 | $19.65M | 0.96% | +650,000+162.5% | Added | View |
| SGMTSAGIMET BIOSCIENCES INC | COM SER A | 2,497,864 | $19.31M | 0.94% | +1,629,844+187.8% | Added | View |
| JBIOJADE BIOSCIENCES INC | COM NEW | 840,350 | $18.67M | 0.91% | +200,394+31.3% | Added | View |
| COGTCOGENT BIOSCIENCES INC | COM | 450,000 | $17.42M | 0.85% | −300,000−40.0% | Reduced | View |
| TVTXTRAVERE THERAPEUTICS INC | COM | 300,000 | $17.04M | 0.83% | 00.0% | Unchanged | View |
| CGEMCULLINAN THERAPEUTICS INC | COM | 875,760 | $15.95M | 0.78% | +94,500+12.1% | Added | View |
| SVRASAVARA INC | COM | 2,512,153 | $15.47M | 0.76% | 00.0% | Unchanged | View |
| IDYAIDEAYA BIOSCIENCES INC | COM | 400,000 | $14.91M | 0.73% | +400,000 | New | View |
| CATXPERSPECTIVE THERAPEUTICS INC | COM NEW | 4,214,582 | $14.37M | 0.70% | +1,050,000+33.2% | Added | View |
| ODTXODYSSEY THERAPEUTICS INC | COMMON STOCK | 766,346 | $14.34M | 0.70% | +766,346 | New | View |
| COGTCOGENT BIOSCIENCES INC | NOTE 1.625%11/1 | – | $13.65M | 0.67% | – | – | View |
| HLXCHELIX ACQUISITION CORP III | USD CL A ORD SHS | 1,250,000 | $13.3M | 0.65% | 00.0% | Unchanged | View |
| EQEQUILLIUM INC | COM | 4,100,000 | $13.12M | 0.64% | +2,873,690+234.3% | Added | View |
| ESTAESTABLISHMENT LABS HLDGS INC | COM | 148,013 | $12.7M | 0.62% | +48,013+48.0% | Added | View |
| CLYMCLIMB BIO INC | COM | 972,000 | $12.67M | 0.62% | +272,000+38.9% | Added | View |
| TEVATEVA PHARMACEUTICAL INDS LTD | SPONSORED ADS | 374,000 | $12.67M | 0.62% | −1,026,000−73.3% | Reduced | View |
| MANEVERADERMICS INC | COMMON STOCK | 100,000 | $12.29M | 0.60% | +30,000+42.9% | Added | View |
| ARWRARROWHEAD PHARMACEUTICALS IN | COM | 150,000 | $12.23M | 0.60% | −50,000−25.0% | Reduced | View |
| OMEROMEROS CORP | NOTE 9.500% 6/1 | – | $12.18M | 0.60% | – | – | View |
| TSHATAYSHA GENE THERAPIES INC | COM SHS | 1,750,000 | $11.92M | 0.58% | +750,000+75.0% | Added | View |
| DMRADAMORA THERAPEUTICS INC | COM NEW | 425,000 | $11.05M | 0.54% | −25,000−5.6% | Reduced | View |
| EPRXEUPRAXIA PHARMACEUTICALS INC | COM | 1,650,000 | $10.91M | 0.53% | +60,995+3.8% | Added | View |
| VERAVERA THERAPEUTICS INC | CL A | 250,000 | $10.73M | 0.52% | 00.0% | Unchanged | View |
| PRQRPROQR THRAPEUTICS N V | SHS EURO | 5,543,936 | $10.31M | 0.50% | +3,089,658+125.9% | Added | View |
| NAMSNEWAMSTERDAM PHARMA COMPANY | ORDINARY SHARES | 275,000 | $9.32M | 0.46% | 00.0% | Unchanged | View |
| KRROKORRO BIO INC | COM | 706,904 | $9.32M | 0.46% | 00.0% | Unchanged | View |
| AVRANTERIS TECHNOLOGIES GLOBAL | COM | 912,397 | $8.99M | 0.44% | 00.0% | Unchanged | View |
| ZURAZURA BIO LTD | CLASS A ORD SHS | 1,464,303 | $8.64M | 0.42% | −1,100,000−42.9% | Reduced | View |
| QUREUNIQURE NV | SHS | 175,000 | $8.06M | 0.39% | +175,000 | New | View |
| ASNDASCENDIS PHARMA A/S | ORD SHS | 30,000 | $8M | 0.39% | +30,000 | New | View |
| IBIOIBIO INC | COM NEW | 4,007,881 | $7.01M | 0.34% | +900,681+29.0% | Added | View |
| GENBGENERATE BIOMEDICINES INC | COM SHS | 400,000 | $6.75M | 0.33% | +50,000+14.3% | Added | View |
| TYRATYRA BIOSCIENCES INC | COM | 200,012 | $6.39M | 0.31% | −57,500−22.3% | Reduced | View |
| SLGLSOL GEL TECHNOLOGIES | SHS NEW | 84,900 | $6.29M | 0.31% | +49,900+142.6% | Added | View |
| SABSSAB BIOTHERAPEUTICS INC | COM NEW | 1,525,000 | $5.95M | 0.29% | +950,000+165.2% | Added | View |
| MGNXMACROGENICS INC | COM | 1,216,606 | $5.62M | 0.27% | +716,606+143.3% | Added | View |
| CRSPCRISPR THERAPEUTICS AG | NAMEN AKT | 100,000 | $5.45M | 0.27% | −50,000−33.3% | Reduced | View |
| NAMSWNEWAMSTERDAM PHARMA COMPANY | *W EXP 11/22/202 | 245,000 | $5.34M | 0.26% | 00.0% | Unchanged | View |
| ASMBASSEMBLY BIOSCIENCES INC | COM NEW | 190,000 | $5.22M | 0.26% | +190,000 | New | View |
| RZLTREZOLUTE INC | COM NEW | 1,000,000 | $5.2M | 0.25% | −547,641−35.4% | Reduced | View |
| DTILPRECISION BIOSCIENCES INC | COM NEW | 646,576 | $5.08M | 0.25% | +48,630+8.1% | Added | View |
| COAGHEMAB THERAPEUTICS HLDGS INC | COM SHS | 138,030 | $5.07M | 0.25% | +138,030 | New | View |
| VRDNVIRIDIAN THERAPEUTICS INC | COM | 250,000 | $4.59M | 0.22% | 00.0% | Unchanged | View |
| AVBPARRIVENT BIOPHARMA INC | COM | 125,000 | $4.34M | 0.21% | −50,000−28.6% | Reduced | View |
| VRCAVERRICA PHARMACEUTICALS INC | COM SHS | 707,338 | $4.33M | 0.21% | 00.0% | Unchanged | View |
| CMPSCOMPASS PATHWAYS PLC | SPONSORED ADS | 301,183 | $4.26M | 0.21% | −807,300−72.8% | Reduced | View |
| MBXMBX BIOSCIENCES INC | COM | 75,000 | $4.14M | 0.20% | −75,000−50.0% | Reduced | View |
| RACCRESEARCH ALLIANCE CORP III | ORD SHS CL A | 370,000 | $3.96M | 0.19% | +370,000 | New | View |
| IMVTIMMUNOVANT INC | COM | 100,000 | $3.85M | 0.19% | 00.0% | Unchanged | View |
| AMANAMANAT ACQUISITION CORP | CL A ORD | 375,000 | $3.81M | 0.19% | +375,000 | New | View |
| BHVNBIOHAVEN LTD | COM | 250,000 | $3.72M | 0.18% | +250,000 | New | View |
| FTHSENSEI BIOTHERAPEUTICS INC | COM NEW | 144,404 | $3.61M | 0.18% | +144,404 | New | View |
| KPTIKARYOPHARM THERAPEUTICS INC | COM NEW | 312,500 | $3.05M | 0.15% | −187,500−37.5% | Reduced | View |
| ALECALECTOR INC | COM | 1,510,000 | $3.04M | 0.15% | +1,010,000+202.0% | Added | View |
| SGPSPYGLASS PHARMA INC | COM SHS | 131,586 | $2.93M | 0.14% | −118,414−47.4% | Reduced | View |
| CRINETICS PHARMACEUTICALS IN22663K107 | COM | 75,000 | $2.81M | 0.14% | 00.0% | Unchanged | – |
| OACCUOAKTREE ACQUISITION CORP III | UNIT 10/04/2029 | 250,000 | $2.75M | 0.13% | 00.0% | Unchanged | View |
| CELCCELCUITY INC | NOTE 0.250% 8/0 | – | $2.28M | 0.11% | – | New | View |
| JATTJATT II ACQUISITION CORP | ORD SHS | 200,000 | $2.27M | 0.11% | +200,000 | New | View |
| NMRANEUMORA THERAPEUTICS INC. | COM | 1,070,651 | $1.82M | 0.09% | +1,070,651 | New | View |
| AMLXAMYLYX PHARMACEUTICALS INC | COM | 98,999 | $1.78M | 0.09% | +98,999 | New | View |
| ANLADLAI NORTYE LTD | ADS | 153,847 | $1.77M | 0.09% | −10,901−6.6% | Reduced | View |
| SPRBSPRUCE BIOSCIENCES INC | COM NEW | 30,000 | $1.62M | 0.08% | +30,000 | New | View |
| EIKNEIKON THERAPEUTICS INC | COM | 98,001 | $1.28M | 0.06% | +98,001 | New | View |
| OKURONKURE THERAPEUTICS INC | COM CL A | 240,963 | $1.1M | 0.05% | 00.0% | Unchanged | View |
| ENGNENGENE THERAPEUT | COM | 600,000 | $1.04M | 0.05% | +600,000 | New | View |
| XFORX4 PHARMACEUTICALS INC | COM NEW | 145,000 | $677.15K | 0.03% | 00.0% | Unchanged | View |
| BOLDBOUNDLESS BIO INC | COM | 250,000 | $625K | 0.03% | +250,000 | New | View |
| LENZLENZ THERAPEUTICS INC | COM | 100,000 | $568K | 0.03% | 00.0% | Unchanged | View |
| QTTBQ32 BIO INC | COM | 27,777 | $353.88K | 0.02% | 00.0% | Unchanged | View |
Options (8)
Put and call positions reported in the same filing. The value is that of the underlying shares, as reported on Form 13F.
| Security | Class | Puts | Calls |
|---|---|---|---|
| MRNAMODERNA INC COM | Stock | $35.02M | $33.26M |
| ARK ETF TR00214Q302 | GENOMIC REV ETF | – | $31.55M |
| LLYELI LILLY & CO COM | Stock | – | $23.99M |
| OMEROMEROS CORP | COM | $13.42M | – |
| ALKSALKERMES PLC | SHS | – | $13.1M |
| QUREUNIQURE NV | SHS | – | $9.21M |
| EVMNEVOMMUNE INC | COM SHS | $6.65M | – |
| SMMTSUMMIT THERAPEUTICS INC | COM | – | $1.46M |
Sold out since Q1 2026 (10)
Positions held at the end of Q1 2026 that are no longer in this filing.
| Security | Class | Shares, Q1 2026 | Value, Q1 2026 | % of portfolio, Q1 2026 |
|---|---|---|---|---|
| CENTESSA PHARMACEUTICALS PLC152309100 | SPONSORED ADS | 1,400,000 | $55.61M | 3.26% |
| ARCELLX INC03940C100 | COMMON STOCK | 362,764 | $41.65M | 2.44% |
| TERNS PHARMACEUTICALS INC880881107 | COM | 562,631 | $29.66M | 1.74% |
| ASNDASCENDIS PHARMA A/S | SPONSORED ADR | 95,000 | $21.73M | 1.27% |
| BBIOBRIDGEBIO PHARMA INC | COM | 150,000 | $11.14M | 0.65% |
| WVEWAVE LIFE SCIENCES LTD | SHS | 1,401,727 | $10.16M | 0.60% |
| CELCCELCUITY INC | NOTE 2.750% 8/0 | – | $7.31M | 0.43% |
| ENGNENGENE HOLDINGS INC | COM | 610,370 | $4.16M | 0.24% |
| CORTCORCEPT THERAPEUTICS INC | COM | 50,000 | $2.02M | 0.12% |
| KEZAR LIFE SCIENCES INC49372L209 | COM | 229,076 | $1.7M | 0.10% |
13F filings by quarter
| Quarter | Filed | Positions | Total value | Changes | Filing |
|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | 104 | $2.04B | vs. Q1 2026 | SEC |
| Q1 2026 | May 14, 2026 | 95 | $1.71B | vs. Q4 2025 | SEC |
| Q4 2025 | Feb 13, 2026 | 86 | $1.39B | vs. Q3 2025 | SEC |
| Q3 2025 | Nov 13, 2025 | 86 | $1.07B | vs. Q2 2025 | SEC |
| Q2 2025 | Aug 13, 2025 | 77 | $676.27M | vs. Q1 2025 | SEC |
| Q1 2025 | May 14, 2025 | 81 | $638.75M | vs. Q4 2024 | SEC |
| Q4 2024 | Feb 13, 2025 | 75 | $640.11M | vs. Q3 2024 | SEC |
| Q3 2024 | Nov 13, 2024 | 77 | $644.52M | vs. Q2 2024 | SEC |
| Q2 2024 | Aug 14, 2024 | 86 | $634.89M | vs. Q1 2024 | SEC |
| Q1 2024 | May 14, 2024 | 77 | $615.08M | vs. Q4 2023 | SEC |
| Q4 2023 | Feb 13, 2024 | 73 | $501.55M | vs. Q3 2023 | SEC |
| Q3 2023 | Nov 14, 2023 | 69 | $306.07M | vs. Q2 2023 | SEC |
| Q2 2023 | Aug 21, 2023Amended | 62 | $254.1M | vs. Q1 2023 | SEC |
| Q1 2023 | May 15, 2023 | 63 | $260.22M | vs. Q4 2022 | SEC |
| Q4 2022 | Feb 13, 2023 | 54 | $218.19M | vs. Q3 2022 | SEC |
| Q3 2022 | Nov 14, 2022 | 47 | $216.94M | vs. Q2 2022 | SEC |
| Q2 2022 | Aug 12, 2022 | 40 | $182.63M | vs. Q1 2022 | SEC |
| Q1 2022 | May 13, 2022 | 48 | $252.21M | vs. Q4 2021 | SEC |
| Q4 2021 | Feb 11, 2022 | 46 | $234.41M | vs. Q3 2021 | SEC |
| Q3 2021 | Nov 12, 2021 | 66 | $251.21M | vs. Q2 2021 | SEC |
| Q2 2021 | Aug 13, 2021 | 62 | $209.94M | vs. Q1 2021 | SEC |
| Q1 2021 | May 14, 2021 | 62 | $204.02M | – | SEC |